MedTrace Logo

Spontaneous Antigenemia in Loiasis

NCT04258670 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2020-07-29

No results posted yet for this study

Summary

This prospective study will enroll and follow 60 loiasis patients with high worm burden to monitor the spontaneous release of filarial antigen in peripheral blood. This study will define the cross-reactive antigen profile of persons with spontaneous loiasis antigenemia, and determine whether it varies with time.

Conditions

  • Loiasis
  • Lymphatic Filariasis

Interventions

OTHER

No intervention

Patients in these cohorts will not be given anti-filariasis therapies because these drugs are not approved for use in patients with high worm burdens (\>20,000 Mf/mL)

Sponsors & Collaborators

  • Doris Duke Charitable Foundation

    collaborator OTHER

  • Centre for Research on Filariasis and other Tropical Diseases

    collaborator UNKNOWN

  • Washington University School of Medicine

    lead OTHER

Principal Investigators

  • Philip Budge, MD, PhD · Washington University School of Medicine

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-23
Primary Completion
2021-05-31
Completion
2021-12-31

Countries

  • Cameroon

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04258670 on ClinicalTrials.gov